| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-26T09:26:30Z |
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
|
Ramalingam S.S; CHIH-HSIN YANG; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A.; J?nne P.A.;Thress K.S;Barrett J.C;Markovets A;Stetson D;Ghiorghiu S;Rukazenkov Y;Mann H;Ohe Y;Nogami N;John T;Kim D.-W;Kurata T;Lee C.K;Chih-Hsin Yang;Ramalingam S.S |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chia-Chi Lin; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
